Literature DB >> 1399724

The significance of post-irradiation prostate biopsy with long-term follow-up.

D A Kuban1, A M el-Mahdi, P Schellhammer.   

Abstract

Ninety-four patients, Stage A2-C, definitively irradiated for adenocarcinoma of the prostate from 1975 to 1981 underwent digitally directed transperineal needle biopsy of a clinically negative prostate gland at least 18 months post-therapy. Ten of 55 patients (18%) treated with Iodine-125 implantation and 7 of 39 patients (18%) externally irradiated were found to have positive biopsy specimens. Overall, clinical local failure occurred in 53% of patients with positive biopsy results but in only 18% with negative specimens, p = .006. The false negative biopsy rate in patients treated with I-125 was nearly three times that for external beam, 24% versus 9%, perhaps because of the greater possibility of inhomogeneous dose distribution with I-125, allowing for a higher degree of sampling error. Actuarial local failure at 5 years was 44% versus 8% with positive and negative biopsies, respectively, and 75% versus 24% at 10 years (p = .0001). The distant metastatic rate was twice as high in biopsy-positive as compared to biopsy-negative patients, 71% versus 35%, p = .015. Actuarially, only 19% of patients with a positive biopsy are NED at 10 years as compared to 62% of those with a negative biopsy (p = .0001). PSA values are supportive in those patients thought to be disease-free. The incidence of positive biopsy and associated local recurrence are in keeping with clinical treatment failure rates as reported in multiple studies to date.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399724     DOI: 10.1016/0360-3016(92)91053-p

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  [Pelvic laparoscopic lymphadenectomy after definitive radiotherapy of prostatic carcinoma].

Authors:  S Dinges
Journal:  Strahlenther Onkol       Date:  1998-07       Impact factor: 3.621

2.  Radiation therapy failure in prostate cancer patients: risk factors and methods of detection.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2002

3.  Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer.

Authors:  Svend O Freytag; Hans Stricker; Mei Lu; Mohamed Elshaikh; Ibrahim Aref; Deepak Pradhan; Kenneth Levin; Jae Ho Kim; James Peabody; Farzan Siddiqui; Kenneth Barton; Jan Pegg; Yingshu Zhang; Jingfang Cheng; Nancy Oja-Tebbe; Renee Bourgeois; Nilesh Gupta; Zhaoli Lane; Ron Rodriguez; Theodore DeWeese; Benjamin Movsas
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-05       Impact factor: 7.038

Review 4.  The role of metabolic imaging in radiation therapy of prostate cancer.

Authors:  V Y Zhang; A Westphalen; L Delos Santos; Z L Tabatabai; K Shinohara; D B Vigneron; J Kurhanewicz
Journal:  NMR Biomed       Date:  2013-08-12       Impact factor: 4.044

5.  Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

Authors:  Kiaran P McGee; Ken-Pin Hwang; Daniel C Sullivan; John Kurhanewicz; Yanle Hu; Jihong Wang; Wen Li; Josef Debbins; Eric Paulson; Jeffrey R Olsen; Chia-Ho Hua; Lizette Warner; Daniel Ma; Eduardo Moros; Neelam Tyagi; Caroline Chung
Journal:  Med Phys       Date:  2021-05-20       Impact factor: 4.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.